This review compared pre-operative (neoadjuvant) systemic therapy with post-operative (adjuvant) therapy for breast cancer using the same regimen. The authors concluded that neoadjuvant and adjuvant therapy appear equivalent in terms of survival and overall disease progression, but neoadjuvant therapy is associated with an increased risk of locoregional recurrence when radiotherapy is used without surgery. The poor quality of the included studies may limit the reliability of these conclusions.
of the participants and the regimens used, but they did not explicitly report the gender of participants. This is important as some men have been included in previous breast cancer trials and the gender of the participants may impact on the outcome of treatment. In addition, the authors did not provide a great deal of detail about the exact treatment regimens used, including doses. The authors did not report the methods used to assess the relevance of studies for inclusion in the review. They described the data extraction procedures in some detail. The validity of the included studies was assessed using appropriate criteria. However, the quality of the included studies was poor with only one study describing the mode of randomisation.
The data analysis methods appear appropriate and the authors took steps to assess factors that might affect the results, such as heterogeneity between the studies. The authors acknowledged the limitations of the review and, overall, their conclusions appear to follow from the information reported. However, the poor quality of the included studies may reduce the overall validity of the conclusions.
Implications of the review for practice and research
Practice: The authors recommended avoiding the use of radiotherapy without any surgical treatment, regardless of response to chemotherapy.
Research: The authors stated that there is little research comparing neoadjuvant therapy with adjuvant therapy using taxanes and other agents with different modes of action. They also suggested that a meta-analysis comparing neoadjuvant therapy with adjuvant therapy using individual patient data may be worthwhile. 
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